Palbociclib: efficacious but predictive biomarkers still needed
Mené sur 521 patientes atteintes d'un cancer métastatique du sein HR+ HER2-, cet essai multicentrique randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du palbociclib au fulvestrant
Several therapeutic options are available for management of premenopausal patients with metastatic hormone-receptor-positive breast cancer, including single-agent endocrine therapy or combination regimens. Single agent treatment with an aromatase inhibitor or tamoxifen has resulted in major improvements in the adjuvant setting but has shown little clinical benefit in metastatic disease. Endocrine therapy is the standard of care for hormone-receptor-positive luminal, HER2-negative metastatic breast cancer.
The Lancet Oncology , commentaire, 2015